VXRT - Can This COVID Vaccine Stock Help Make You Rich?
There are a handful of companies that dominate the coronavirus vaccine market. The two leaders -- Pfizer and Moderna -- expect to generate a combined $55.5 billion in sales this year. Is there any room left in this space for newcomers? The answer is a resounding yes. First, vaccines aren't as readily available in many developing countries as in the United States.
But there's another reason too. Vaccine hesitancy prevents many people from getting inoculated. A May 2021 Gallup poll found that 24% of adults in the U.S. were not planning to get vaccinated, with most of them saying they were unlikely to reconsider. One company looking to make headway into the vaccine-hesitant crowd is Vaxart (NASDAQ: VXRT) . Let's discuss the biotech's strategy to enter the coronavirus vaccine market and its implications for investors.
For further details see:
Can This COVID Vaccine Stock Help Make You Rich?